Related Experiment Video
Updated: Feb 10, 2026

Author Spotlight: Assessment of Visual Acuity in Central Vision Loss Through Motion-Based Peripheral Vision Testing
Published on: February 23, 2024
Real study: Re-treatment evaluated on visual acuity for Lucentis® in neovascular AMD
D Bellocq1, F De Bats2, M Rabilloud3
1Department of Ophthalmology, Croix-Rousse University Hospital, Hospices Civils de Lyon, University of Lyon I, 69004 Lyon, France; CNRS UMR 5510 Mateis, 69621 Villeurbanne, France.
Monthly injections of ranibizumab (Lucentis®) guided by visual acuity (VA) and absence of exudation in neovascular age-related macular degeneration (AMD) achieved significant VA gains. Further gains were minimal once stability was reached, suggesting an effective treatment regimen.
Area of Science:
- Ophthalmology
- Retinal Diseases
- Pharmacological Treatments
Background:
- Neovascular age-related macular degeneration (AMD) is a leading cause of vision loss.
- Current treatment protocols often involve pro re nata (PRN) injections, leading to variable outcomes.
- Optimizing treatment regimens is crucial for preserving visual acuity in AMD patients.
Purpose of the Study:
- To evaluate the efficacy of a monthly ranibizumab (Lucentis®) injection strategy in neovascular AMD.
- To determine the optimal duration of treatment until stable visual acuity (VA) and absence of exudation are achieved.
- To assess the value of a VA-guided regimen in managing neovascular AMD.
Main Methods:
- Prospective, single-center, non-controlled trial involving treatment-naïve neovascular AMD patients.
- Monthly assessments of VA and spectral domain optical coherence tomography (SD-OCT).
- Initial three monthly ranibizumab injections followed by continued monthly injections until three consecutive stable VA results without exudation.
Main Results:
- Fifteen of 21 patients (71%) showed good anatomical response.
- A mean VA gain of +14 logarithm of the exponent (Le) was achieved prior to reaching stability.
- No significant additional VA gain was observed after achieving stability and absence of exudation.
Conclusions:
- A VA-guided, monthly ranibizumab regimen may be effective in managing neovascular AMD.
- This approach might prevent the VA decline seen in the first year of PRN treatment protocols.
- The study suggests that treatment can be guided by achieving stable VA and absence of exudation.
Related Concept Videos
Real Number System
Real Number Operations
Case Studies
Open Angle Glaucoma: Treatment
Drugs such as carbonic anhydrase inhibitors, α2- and...
Treatment Resistant Cancers
Real Zeros of Polynomials

